Opioid Agonist Therapy Adherence Trajectories Among Commercially and Publicly Insured People Living With Hepatitis C in the United States.

BACKGROUND

Hepatitis C virus (HCV) infection is a public health concern, with people living with opioid use disorder having a higher risk of infection. Despite the cooccurrence of HCV and opioid use disorder, little is known about the treatment patterns for the disorder in this population. This study characterized opioid agonist therapy adherence trajectories over 15 months following opioid agonist therapy initiation among people living with HCV and opioid use disorder and described the baseline characteristics of the patients within distinct opioid agonist therapy adherence trajectories.

METHODS

We used Merative MarketScan healthcare claims data from 2015 to 2019 to identify distinct medication treatment adherence trajectories via growth mixture modeling among 5,495 people who initiated opioid agonist therapy for opioid use disorder and were living with HCV.

RESULTS

Our models identified three distinct opioid agonist therapy adherence trajectories over the 15 months of follow-up. We named these trajectories rapidly declining opioid agonist therapy adherence (class 1; N = 1,904; 35%), steadily declining opioid agonist therapy adherence (class 2; N = 2,150; 39%), and consistently high opioid agonist therapy adherence (N = 1,441; 26%). People in the consistently high adherence group were older, more likely to be women (vs. men), White (vs. Black), had HCV direct-acting antiviral treatment during the baseline period, and had the lowest prevalence of nonopioid substance use diagnoses.

CONCLUSIONS

These results may inform support for populations with elevated baseline risk of low opioid agonist therapy adherence during follow-up.